Transdermal oxybutynin: Topical therapy for overactive bladder syndrome

Expert Review of Obstetrics and Gynecology

Volumn 3, Issue 2, 2008, Pages 175-179

  Wagg, Adrian ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Incontinence; Overactive bladder; Oxybutynin; Transdermal therapy; Urinary

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ANTICHOLINERGIC SYNDROME; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; ARTICLE; BEHAVIOR THERAPY; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; LIFESTYLE MODIFICATION; MORBIDITY; OVERACTIVE BLADDER; PHARMACODYNAMICS; PREVALENCE; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

EID: 49149084268     PISSN: 17474108     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474108.3.2.175     Document Type: Article

References (29)

1. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 50(6), 1306-1314 (2006).
2. Horrocks S, Somerset M, Stoddart H, Peters TJ. What prevents older people from seeking treatment for urinary incontinence? A qualitative exploration of barriers to the use of community continence services. Fam. Pract. 21 (6) 689-696 (2004).
3. Shaw C, Tansey R, Jackson C, Hyde C, Allan P,. Barriers to help seeking in people with urinary symptoms. Fam. Pract. 18(1), 48-52 (2001).
4. Diokno AC, Burgio K. Fultz NH, Kinchen KS, Obenchain R, Bump RC. Medical and self-care practices reported by women with urinary incontinence. Am. J. Manag. Care 10, 69-78 (2004).
5. Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst. Rev. 1, CD001308 (2004).
6. Jarvis GJ, Millar DR. Controlled trial of bladder drill for detrusor instability. BMJ 281(6251), 1322-1323 (1980).
7. Borrie MJ, Bawden M, Speechley M et al. Interventions led by nurse continence advisers in the management of urinary incontinence: a randomized controlled trial. CMAJ 166(10), 1267-1273 (2002).
8. National Collaborating Centre for Women and Children's Health Urinary incontinence in Women. NICE Clinical Guideline 40. NICE, London, UK (2006).
9. Burgio K, Locher JL, Goode PS. Combined behavioural and drug therapy for urgency incontinence in older women. J. Am. Geriatr. Soc. 48, 370-374 (2000).
10. Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive, bladder. BJU Int. 93(3), 303-310 (2004).
11. 3 selective receptor antagonist. Eur. Urol. 48, 471-477 (2005).
12. Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 60(5 Suppl. 1), 82-88 (2002).
13. Yoshimura N. Lower urinary tract symptoms (LUTS) and bladder afferent activity. Neurourol. Urodyn. 6(Suppl.), 908-913 (2007).
14. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br. J. Obstet. Gynaecol. 104, 988-993 (1997).
15. Bang LM, Easthope SE, Perry CM. Transdermal oxybutynin: for overactive bladder. Drugs Aging 20(11), 857-864 (2003).
16. Davila GW, Daugherty CA, Sanders SW; Transdermal Oxybutynin Study Group. A short-term, multicentre, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urgency urinary incontinence. J. Urol. 166(1), 150-151 (2001).
17. Zobrist RH, Quan D, Thomas HM, Stanworth S, Sanders SW. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm. Res. 20(1), 103-109 (2003).
18. Mizushima H, Inoue K, Ishizuka H. The effects of external heating on the permeation of oxybutynin through human epidermal membrane. Biol. Pharm. Bull. 30(3), 612-615 (2007).
19. Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin. Proc. 78, 696-702 (2003).
20. Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J. Urol. 23(4), 263-270 (2005).
21. Dmochowski RR, Davila GW, Zinner NR et al. Efficacy and safety of transdermaloxybutynin in patients with urgency and mixed urinary incontinence. J. Urol. 168, 580-586 (2002).
22. Dmochowski RR, Sand PK, Zinner NR et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urgency and mixed urinary incontinence. Urology 62(2), 237-242 (2003).
23. Davila GW, Dmochowski RR, Sanders SW. Influence of age on improvements in overactive bladder symptoms and adverse events during oxybutynin transdermal system treatments. Proceedings of the 56th American College of Obstetricians and Gynecologists Conference. S163 Los Angeles, CA, USA, 4-8 May 2002.
24. Dmochowski RR, Davila GW, Sanders SW. Anticholinergic and other adverse events with transdermal oxybutynin for overactive bladder in patients >70 years. J. Am. Geriatr. Soc. 50, 539 (2002).
25. Newman DK. Patient perceptions on new therapeutic options for the control of overactive bladder. Proceedings of the Society of Urologic Nurses and Associates Annual Conference. San Antonio, TX, USA, 26 March 2003.
26. Sand P, Zinner N, Newman D et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 99(4), 836-844 (2007).
27. Srikrishna S, Robinson D, Cardozo L, Vellan M. OAB: are we giving women what they want? Neurourol. Urodyn. 26, 651-652 (2007).
28. 3 receptor subtype. Proceedings of the Annual Meeting of the International Continence Society. Heidelberg, Germany, 2002 (Abstract 445).
29. 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn. Schmiedebergs Arch. Pharmacol. 366, 97-103 (2002).